Improved efficacy against malignant brain tumors with EGFRwt/EGFRvIII targeting immunotoxin and checkpoint inhibitor combinations

ConclusionsThese data support the development of D2C7-IT and immune checkpoint blockade combinations for patients with malignant glioma.

Source: Journal for Immunotherapy of Cancer - May 28, 2019 Category: Cancer & Oncology Source Type: research